Reviewed by a board-certified obesity medicine physician. Last updated March 2026.

Why Side Effects Happen

GLP-1 receptor agonists slow gastric emptying, alter appetite signaling in the brain, and change how your body processes food. These mechanisms produce the weight loss effect, but they also cause the gastrointestinal symptoms that most patients experience during the first weeks of treatment.

The critical insight from clinical trial data is that side effects are dose-dependent and time-limited. Most patients who tolerate the titration period go on to use the medication long-term with minimal or no ongoing symptoms [1].

Week 1-2: First Dose

All GLP-1 treatments begin at the lowest available dose. For semaglutide (Wegovy), that is 0.25 mg weekly. For tirzepatide (Zepbound), it is 2.5 mg weekly.

Common experiences at starting dose:

  • Mild nausea, usually occurring 1-3 hours after the injection and lasting several hours
  • Reduced appetite (this is the medication working as intended, not a side effect)
  • Mild headache in some patients
  • Occasional fatigue

How common: In the STEP 1 trial, 44% of semaglutide patients reported nausea at some point during treatment, but only 4.5% discontinued due to gastrointestinal events [1]. At the starting dose, rates are substantially lower.

Management:

  • Take your injection in the evening so peak nausea occurs during sleep
  • Eat smaller portions throughout the day rather than large meals
  • Avoid greasy, fried, or very sweet foods, which can worsen nausea
  • Stay hydrated with water and clear fluids

Week 3-4: Adaptation

Your body begins adjusting to the medication at the starting dose. Most patients report that initial nausea improves or resolves by the end of week 4.

New symptoms that may emerge:

  • Constipation (affects 10-24% of patients [2]) as gastric motility slows
  • Bloating or early fullness after small meals
  • Mild acid reflux in some patients

Management:

  • Increase fiber intake gradually through fruits, vegetables, and whole grains
  • Aim for 64 or more ounces of water daily
  • Consider a stool softener if constipation persists (consult your provider)
  • Walking 20-30 minutes daily helps with both constipation and overall tolerability

Week 5-8: First Dose Escalation

The titration schedule calls for a dose increase, typically at week 4 or 5. This is when many patients experience a temporary return of nausea.

What to expect:

  • Nausea recurrence that is typically milder than the initial onset and resolves faster
  • Possible diarrhea or loose stools for several days after the increase
  • Noticeable decrease in appetite at the higher dose
  • Weight loss becomes more apparent, typically 2-4% of starting weight by week 8

Key guidance: If side effects at the current dose have not resolved, do not increase. Talk to your provider about extending the time at your current dose before escalating. The titration schedule in the prescribing information is a guide, not a rigid requirement [3].

Month 2-3: Building Toward Target Dose

Most patients go through 3-5 dose increases over 16-20 weeks to reach their target dose. Each increase may cause a brief flare of GI symptoms, but the pattern is consistent: 3-7 days of mild symptoms followed by adaptation.

Typical experience by month 3:

  • GI symptoms are absent or mild for most patients
  • Weight loss of 5-10% of starting body weight
  • Eating patterns have stabilized around smaller portions
  • Energy levels are often improved

Less common symptoms that may appear:

  • Acid reflux or GERD symptoms (occurs in approximately 5-10% of patients)
  • Changes in taste preferences
  • Mild dizziness, usually related to reduced caloric intake rather than the medication directly

Month 3-6: Target Dose Maintenance

Patients who reach their target dose and tolerate it well typically report the most significant weight loss during this window.

Side effects at this stage are generally minimal. The two concerns that may emerge are related to the weight loss itself, not the medication:

Hair thinning (telogen effluvium): Rapid weight loss can trigger temporary hair shedding, typically appearing 3-6 months after significant weight loss begins. This is a known response to caloric restriction, not a direct drug effect, and hair regrowth occurs after weight stabilizes. Ensure adequate protein intake (60-100g daily) and consider a biotin supplement.

Muscle loss: GLP-1 medications reduce appetite broadly, which can lead to inadequate protein intake and loss of lean muscle mass. The STEP 1 trial found that approximately 39% of weight lost was lean mass [1]. Resistance training 2-3 times per week and high protein intake are the most effective countermeasures.

Rare but Serious Side Effects

These affect a small percentage of patients but require immediate medical attention:

Pancreatitis: Severe, persistent abdominal pain radiating to the back, often with vomiting. Reported in fewer than 0.5% of clinical trial participants [2]. Seek emergency care.

Gallbladder disease: Rapid weight loss increases gallstone risk regardless of how the weight is lost. Symptoms include pain in the upper right abdomen after meals, especially fatty meals. Contact your provider.

Severe allergic reaction: Facial swelling, difficulty breathing, or widespread rash. Extremely rare. Seek emergency care.

Thyroid concerns: GLP-1 medications carry a boxed warning based on thyroid C-cell tumors observed in rodent studies [3]. Report any new neck lump, persistent hoarseness, or difficulty swallowing to your provider. No causal link has been established in humans.

When to Contact Your Provider

  • Nausea or vomiting that prevents eating or drinking for more than 24 hours
  • Severe or worsening abdominal pain
  • Signs of dehydration (dark urine, dizziness, rapid heartbeat)
  • Symptoms that worsen rather than improve with each passing week
  • Any new or unexpected symptom

Find a GLP-1 provider near you who offers ongoing monitoring and side effect management as part of their treatment program.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication.

Sources

  1. Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)." NEJM. 2021;384:989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
  2. FDA. Wegovy Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
  3. FDA. Zepbound Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf
  4. Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)." NEJM. 2022;387:205-216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
  5. CDC. Adult Obesity Prevalence Maps. https://www.cdc.gov/obesity/adult-obesity-facts/index.html